These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 3290717)
21. Experience with cyclophosphamide in multiple sclerosis: the cons. Likosky WH Neurology; 1988 Jul; 38(7 Suppl 2):14-8. PubMed ID: 3290708 [TBL] [Abstract][Full Text] [Related]
22. The use of digital technology to asses the severity of the Experimental Allergic Encephalomyelitis (EAE) spinal cord lesion. Mohamed A; Tarhuni H; Dufan T; Benghuzzi H; Tucci M Biomed Sci Instrum; 2004; 40():419-23. PubMed ID: 15133994 [TBL] [Abstract][Full Text] [Related]
23. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Madsen LS; Andersson EC; Jansson L; krogsgaard M; Andersen CB; Engberg J; Strominger JL; Svejgaard A; Hjorth JP; Holmdahl R; Wucherpfennig KW; Fugger L Nat Genet; 1999 Nov; 23(3):343-7. PubMed ID: 10610182 [TBL] [Abstract][Full Text] [Related]
24. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage. Joshi N; Usuku K; Hauser SL Ann Neurol; 1993 Sep; 34(3):385-93. PubMed ID: 7689820 [TBL] [Abstract][Full Text] [Related]
25. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros. Khatri BO Neurology; 1988 Jul; 38(7 Suppl 2):50-2. PubMed ID: 3290715 [TBL] [Abstract][Full Text] [Related]
31. Effects of experimental recombinant interferons on multiple sclerosis. Johnson KP; Panitch HS Trans Am Clin Climatol Assoc; 1989; 100():171-6. PubMed ID: 2479162 [No Abstract] [Full Text] [Related]
32. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Hohol MJ; Khoury SJ; Cook SL; Orav EJ; Hafler DA; Weiner HL Ann N Y Acad Sci; 1996 Feb; 778():243-50. PubMed ID: 8610977 [No Abstract] [Full Text] [Related]
33. Is there a place for 'immuno' in the immunotherapy of multiple sclerosis? Forsthuber TG; Muraro P Immunotherapy; 2009 May; 1(3):329-31. PubMed ID: 20635950 [No Abstract] [Full Text] [Related]
34. Antigen specific immunotherapy of multiple sclerosis. Steinman L; Conlon P J Clin Immunol; 2001 Mar; 21(2):93-8. PubMed ID: 11332658 [TBL] [Abstract][Full Text] [Related]
35. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Arnon R Immunol Lett; 1996 Apr; 50(1-2):1-15. PubMed ID: 8793553 [No Abstract] [Full Text] [Related]
40. [The clinical picture of MS disease is now more complete]. Panelius M; Salmi AA Duodecim; 1992; 108(1):73-5. PubMed ID: 1365986 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]